Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
- Toni K. Choueiri
- , Todd M. Bauer
- , Kyriakos P. Papadopoulos
- , Elizabeth R. Plimack
- , Jaime R. Merchan
- , David F. McDermott
- , M. Dror Michaelson
- , Leonard J. Appleman
- , Sanjay Thamake
- , Rodolfo F. Perini
- , Naseem J. Zojwalla
- , Eric Jonasch
- Dana-Farber Cancer Institute
- Sarah Cannon Research Institute
- South Texas Accelerated Research Therapeutics
- University of Miami
- Beth Israel Deaconess Medical Center
- Massachusetts General Hospital
- University of Pittsburgh
- Merck & Co.
- University of Texas MD Anderson Cancer Center
- Dana-Farber/Brigham and Women's Cancer Center
- Harvard University
- Cancer Center
- Brigham and Women's Hospital
- Tennessee Oncology
- Dana-Farber/Harvard Cancer Center
- Massachusetts General Hospital Cancer Center
- University of Texas Health Science Center at Houston
- The University of Texas M. D. Anderson CancerCenter
Research output: Contribution to journal › Letter › peer-review
265
Scopus
citations